Biopharmaceutical Industry

• 11/3/2024

  Pfizer CEO Remains Optimistic Amid Activist Investor Criticism

• 11/1/2024

  Eli Lilly’s Weight Loss and Diabetes Drugs Miss Sales Expectations Amid Inventory Issues

• 10/25/2024

  Viatris Inc. Stock Update: Time to Reconsider?

• 10/25/2024

  2 Ultra-High-Yield Healthcare Stocks: 1 to Buy, 1 to Avoid

• 10/23/2024

  Sangamo Therapeutics: From Struggle to Billion-Dollar Potential

• 10/23/2024

  “Revolutionizing Alzheimer’s Treatment: BioArctic’s Leqembi Breakthrough”

• 10/22/2024

  Seth Klarman Dumps Alphabet, Bets Big on Undervalued Pharma Stock

• 10/21/2024

  Johnson & Johnson Q3 Earnings: Steady Growth Ahead

• 10/21/2024

  Pfizer Investment: Why I’m Bullish on the Pharma Giant

• 10/20/2024

  Navigating AI’s Uncertain Future: Cash Burn and Clinical Hurdles